Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis

Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis

Global Epilepsy Drugs Market is envisioned to reach US$ 10.28 Billion by 2030, according to Renub Research. Globally, health systems struggle to provide critical medical offerings and ensure access to remedies for chronic conditions like epilepsy. Characterized by recurrent seizures, epilepsy entails unexpected, transient modifications in brain function, leading to convulsions, loss of recognition, or uncommon sensations and behaviors. Despite being diagnosed as a public fitness priority by the World Health Organization, epilepsy frequently lacks good enough interest and support. So, epilepsy drugs are prescribed to manage seizures by stabilizing brain electrical activity, helping sufferers manage their condition.

Global epilepsy drugs market is projected to expand at a CAGR of 4.37% from 2024 to 2030

As the world's population grows and grows old, the prevalence of epilepsy is anticipated to increase due to an expanding market. People elderly 65 and above have a higher incidence rate of epilepsy. According to the Centers for Disease Control and Prevention (CDC) record of 2023, epilepsy is one of the most common neurological issues worldwide, affecting over 1% of Americans. Furthermore, the World Health Organization reports that epilepsy affects about 50 million people globally, surpassing the number of people with cerebral palsy, multiple sclerosis, and Parkinson's disease combined.

Second-generation epilepsy drugs dominate the global epilepsy drug market. This is because of advanced efficacy, tolerability, simpler dosing, decreased danger of interactions, and improved seizure control. However, third-generation drugs have received prominence for advanced efficacy, protection, and tailored treatment. A study by Science Direct indicates a notable rise in the prescription frequency of third-generation anti-seizure medication (ASMs), increasing from 59.3% to 84.2%. This surge coincided with a decline in the frequency of first- and second-generation ASMs, dropping from 5.4% to 2.1% and 34.9% to 12.6%, respectively. Tailored to specific seizure types, these drugs feature once-daily dosing and fewer interactions, making them more appealing to patients and providers and driving increased market prominence. Hence, the global epilepsy drugs market reached US$ 7.62 Billion in 2023.

Moreover, authorities' approvals for new drugs power market growth, spurred by elevated recognition and diagnosis rates. Organizations like the Epilepsy Foundation, Epilepsy Society, Epilepsy Association of Western and Central PA, and Narayana Health promote education and attention. This has multiplied the patient pool, prompting pharmaceutical agencies to spend money on R&D, introducing novel drugs with advanced efficacy, fewer side effects, and affordability, consequently increasing remedy alternatives and market growth. For instance, Angelini Pharma announced a USD 505.5 million investment in JCR Pharmaceuticals Co., Ltd. for a brand-new epilepsy treatment in May 2023.

Also, technological improvements in diagnostics and monitoring gadgets enhance epilepsy detection and management, driving the epilepsy drugs market. For example, National Institutes of Health (NIH)-funded researchers utilized A.I. to locate mouse behavioral ""fingerprints,"" aiding early identity without expecting seizures, requiring only one hour of video recording. Published in Neuron, the study highlights progressed 3-D video evaluation over traditional human observation-based techniques for epilepsy research.

The third generation of epilepsy drugs may seriously impact the global market

Based on the drug category, the global epilepsy drugs market is fragmented into First-Generation Drugs, Second-Generation Drugs, and Third-Generation Drugs. The third-generation class may develop significantly in the global epilepsy drugs market. Enhanced efficacy, protection, and tailor-made remedy alternatives drive accelerated adoption, making it a distinguished and increasing section in addressing neurological situations.

Focal seizures have the potential to constitute a significant portion of the global market for epilepsy drugs

The global epilepsy drugs market is segmented by seizure types into Focal Seizures, Generalized Seizures, and Non-Epileptic Seizures. Focal seizures may represent a considerable segment of the worldwide epilepsy drugs market due to their incidence and the desire for powerful treatment alternatives to control signs and symptoms and improve the effects on the affected person.

Drug shops and retail pharmacies could be expected to retain a substantial portion of the global epilepsy drugs market

The global epilepsy drugs market is categorized by distribution channels into hospital pharmacies, drug stores, retail pharmacies, and online providers. Drug shops and retail pharmacies may be predicted to keep a considerable proportion of the market. This is owed to their accessibility, which provides handy access to medicines for people with epilepsy.

Asia Pacific region is expected to witness one of the highest growth rates in the global market for epilepsy drugs

By countries, the global epilepsy drugs market is divided into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand), Latin America (Brazil, Mexico, Argentina), Middle East & Africa (South Africa, Saudi Arabia, United Arab Emirates), and Rest of the World. The Asia Pacific region is anticipated to experience one of the highest increases in the global epilepsy drugs market. This is because of favorable government initiatives, including the Intersectoral Global Action Plan on Epilepsy, the Global Campaign Against Epilepsy, and the launch of recent-generation anti-epileptic drugs. Besides, patient cognizance of powerful epilepsy drugs and the high unmet medical desires in the rising economies of India and China are propelling the epilepsy drugs market boom in the surroundings.

Key Players

Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, G.W. Pharmaceuticals Plc., Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., GSK plc, Novartis AG., and Pfizer Inc. are the businesses in the global epilepsy drugs market.

• In January 2022 - UCB acquired Zogenix for $1.9B to expand its epilepsy product portfolio with Fintepla, a treatment for seizures associated with Dravet syndrome, a rare type of epilepsy in children.

Drug Category – Global Epilepsy Drugs Market breakup in 4 viewpoints:

1. First Generation Drugs
2. Second Generation Drugs
3. Third Generation Drugs

Seizure Types – Global Epilepsy Drugs Market breakup in 3 viewpoints:

1. Focal Seizures
2. Generalized Seizures
3. Non-Epileptic Seizures

Distribution Channel – Global Epilepsy Drugs Market breakup in 3 viewpoints:

1. Hospital Pharmacies
2. Drug Stores and Retail Pharmacies
3. Online Providers

Countries – Global Epilepsy Drugs Market breakup in 26 viewpoints:

1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherland
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 UAE
5.3 South Africa

6. Rest of the World

All the Key players have been covered from 3 Viewpoints:

• Overview
• Recent Development
• Revenue Analysis

Company Analysis:

1. Eisai Co., Ltd.
2. UCB Inc.
3. H. Lundbeck A/S
4. GW Pharmaceuticals Plc.
5. Abbott Laboratories
6. Alkem Laboratories Limited
7. Bausch Health Companies Inc.
8. GSK plc
9. Novartis AG.
10. Pfizer Inc.